Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale.

Abstract

In a pilot study the effect of a bolus dose of amrinone intravenously (IV), 0.5 or 1 mg/kg body weight, in 10 patients with chronic obstructive lung disease and cor pulmonale was evaluated. We found that the higher dose of 1.0 mg/kg IV significantly (P less than 0.05) decreased the mean pulmonary artery pressure and pulmonary wedge pressure without significant changes in cardiac output, in systemic blood pressure or in arterial blood gas values. No adverse effects were recorded in any of the patients.

• Authors: W Van Mieghem, P Van den Brande, R De Waele, J Meirhaeghe, M Arens, M Demedts
• Journal: Acta cardiologica (Acta Cardiol) Vol. 45 Issue 1 Pg. 57-64 ( 1990) ISSN: 0001-5385 [Print] England
• PMID: 2316304 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Amrinone

Topics

• Aged
• Amrinone (administration & dosage, therapeutic use)
• Cardiac Output (drug effects)
• Dose-Response Relationship, Drug
• Female
• Humans
• Lung Diseases, Obstructive (complications, drug therapy)
• Male
• Middle Aged
• Pilot Projects
• Pulmonary Heart Disease (drug therapy, etiology)
• Pulmonary Wedge Pressure (drug effects)
• Vascular Resistance (drug effects)